{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To test for loss of one or both HLA haplotypes in patients who relapse post-transplant and examine the relapse in the context of the characteristics of the 2 donors","groups":[{"description":"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.\n\nTRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.\n\nGVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28.","id":"OG000","title":"Allogeneic HSCT Using Two Related Donors"}],"reportingStatus":"POSTED","timeFrame":"1 year post transplant","title":"Assessment for Tumor Escape Mechanisms","type":"SECONDARY"}